Eisai
Eisai and Purdue reveal positive Phase 3 data in insomnia
February 7, 2019Research and Development Eisai, Purdue Pharma, insomnia, lemborexant, pharma
Partners Eisai and Purdue Pharma have lifted the curtain on Phase 3 clinical data on their jointly developed therapy lemborexant …
Top Ten most popular articles on Pharmafile.com this week!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …
Pharma in 2018: Looking back, looking forward
December 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, Alligator Bioscience, Eisai, Gilead, Mundipharma, pharma
2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 …
The December issue of Pharmafocus is available to read online now!
December 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eisai, GSK, Gilead, Mundipharma, Pharmafocus, mesothelioma, pharma
The December edition of Pharmafocus is live and available to read online now!Brexit continues to dominate the headlines inside and …
Eisai’s Lenvima wins over NICE in liver cancer in just three months
November 9, 2018Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …
Top Ten most popular articles on Pharmafile.com this week
August 31, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top ten
Eight months of 2018 down – where has the year gone? As we move from August into September, and a …
Eisai’s weight loss drug lorcaserin found safe in major study
August 28, 2018Manufacturing and Production, Research and Development, Sales and Marketing Eisai, lorcaserin, safety, study, weight loss
Eisai’s weight loss drug lorcaserin does not increase people’s risk of major cardiovascular events according to a study of 12,000 …
Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials
July 26, 2018Research and Development Alzheimer's disease, BAN2401, Biodgen, Eisai, phase 2, research
An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …
Eisai forms partnership to find new tuberculosis treatment
April 13, 2018Medical Communications, Research and Development Colorado State University, Eisai, broad institute, pharma, tuberculosis, university of chicago
Eisai has teamed up with the Broad Institute, the Mycobacteria Research Laboratories at Colorado State University and the University of …
Eisai and MSD team up to combine Lenvima and Keytruda in cancer
March 8, 2018Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma
Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …
NICE rejects Eisai’s Halaven in earlier setting for metastatic breast cancer
February 22, 2018Sales and Marketing Brest cancer, Cancer, Eisai, Halaven, NICE, pharma
NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast …
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
Eisai and Biogen Alzheimer’s drug stumbles at P2
December 21, 2017Medical Communications, Research and Development Biogen, Eisai, biotech, drugs, pharma, pharmaceutical
Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …
NICE refuses Eisai’s breast cancer drug in new indication
November 28, 2017Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma
NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …
Real-world data prove efficacy of Eisai and Bial’s epilepsy treatment
September 6, 2017Research and Development Bial, Eisai, Zebinix, epilepsy, pharma
Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
